Mumbai: Johnson & Johnson MedTech has onboarded Qure.ai as a
strategic partner with Johnson & Johnson Private Limited, a Johnson & Johnson company, to enhance early detection of lung cancer in India.This
collaboration brings together cutting-edge AI and medical technology, helping
identify lung cancer at its most treatable stage.

This
initiative is part of Project BreatheEZ, a broader strategic collaboration
between Qure.ai and Johnson & Johnson MedTech, and designed to establish AI-led
Incidental Pulmonary Nodule (IPN) Detection clinics across
leading hospitals in India. These clinics will act as integrated screening
hubs, optimizing early detection, triaging, and follow-up care for lung cancer
patients. As
part of this collaboration, Qure.ai’s AI technology will be deployed across 10
hub medical centers in India, with an additional 20 supporting spoke sites. The
first such clinic has been launched in Thangam Cancer Centre in
Namakkal, Tamil Nadu.

In
India, one in nine persons is likely to be diagnosed with cancer in their
lifetime. It is an increasing health concern, and the projected cancer burden
is expected to rise from 26.7 million DALYs (Disability-Adjusted Life Years) in
2021 to 29.8 million in 2025. This growing health challenge needs
innovative solutions to improve early detection and ultimately save lives. Traditional diagnostic methods often fail to
detect lung cancer at an early stage, leading to delays in treatment. 

“By
harnessing of artificial intelligence in the modalities of X-Ray & CT scans,
Johnson & Johnson MedTech India & Qure.ai are enabling the detection of
potential lung nodules that might otherwise be missed. This happens through
flagging risky nodules in X-Rays and CT Scans that can potentially turn out to
be malignant. It also introduces the concept of structured IPN clinics where
there is a proactive impetus towards incidental screening of early-stage lung
cancer. This partnership embodies Johnson & Johnson MedTech’s commitment to
enhancing early lung cancer detection, ultimately transforming the standard of lung
cancer care,” the release stated.

Anuj Virmani, Managing Director, India, Johnson
& Johnson MedTech, said, “Lung cancer continues to be one of the leading
causes of cancer in both men and women. In India, where access to advanced
healthcare facilities is often limited, especially in tier-2 and tier-3 cities,
patients face significant challenges in receiving timely and effective
diagnosis, which further delays access to treatment. Our collaboration with
Qure.ai is a testament to our
commitment to advancing healthcare through innovative solutions continues to
drive impactful collaborations and integrating our solutions in lung cancer.”